Skip to main content

Table 1 Comparison of QALY outcomes across various scenarios of surveillance for adenoma patients and CRC risk

From: Evidence-based sizing of non-inferiority trials using decision models

Strategy

10y cumulative incidence

Life-years (per 1000 pt)

QALYs lost due to surveillance (per 1000 pt)

QALYs lost due to complications (per 1000 pt)

QALYs lost due to treatment (per 1000 pt)

QALYs (per 1000 pt)

Difference in QALYs (per 1000 pt)

5-yearly surveillance

1.0%

22,424

26.3

0.3

54.1

22,343.2

Reference Strategy

10-yearly surveillance

1.0%

22,424

18.0

0.2

54.1

22,351.5

8.3

10-yearly surveillance

1.5%

22,412

18.1

0.2

55.8

22,338.1

−5.1

10-yearly surveillance

1.3%

22,419

18.0

0.2

49.8a

22,351.0

8.1

10-yearly surveillance

1.42%

22,415

18.1

0.2

53.5a

22,343.1

0.0

  1. 10y: 10-year; QALYs: Quality-adjusted life-years; pt.: patients
  2. a QALY lost to treatment are not necessarily higher with higher CRC incidence, because they also depend on the stage distribution of CRC cases and time spent in each CRC state. Higher CRC incidence may lead to fewer life-years with CRC treatment because of higher mortality from CRC